top of page
Leading the Way in Intratumoral Radiotherapeutics
News
Categories
Sign up
Featured Posts
Archive
Follow Us
Alpha Tau to Present at Jefferies Global Healthcare Conference
JERUSALEM, May 28, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
May 28
Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update
- Interim Jan-2025 results from three trials of Alpha DaRT® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium...
May 20
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors
JERUSALEM, May 12, 2025 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS , DRTSW ), ("Alpha Tau" or the "Company"), the developer of the...
May 13
Alpha Tau to Participate in May Investor Conferences
JERUSALEM, May 6, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
May 6
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
- Investment comes at a pivotal moment for Alpha Tau, which is experiencing remarkable growth on multiple fronts, with four active U.S....
Apr 28
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
JERUSALEM, April 2, 2025 – Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy...
Apr 2
Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update
- Interim results from three trials exploring the use of Alpha DaRT ® in treating pancreatic cancer showing high disease control rate,...
Mar 13
Alpha Tau to Participate in March Investor Conferences
JERUSALEM, February 27, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Feb 27
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
Feb 24
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Coh
Feb 3
bottom of page